Earl Ray Dorsey

List of Publications by Year
in descending order

129 papers	14,357 citations	57758 44 h-index	22832 112 g-index
134 all docs	134 docs citations	134 times ranked	18443 citing authors

#	Article	IF	Citations
1	Multiple Wearable Sensors in Parkinson and Huntington Disease Individuals: A Pilot Study in Clinic and at Home. Digital Biomarkers, 2017, 1, 52-63.	4.4	1,794
2	Global, regional, and national burden of Parkinson's disease, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology, The, 2018, 17, 939-953.	10.2	1,573
3	The State of US Health, 1990-2016. JAMA - Journal of the American Medical Association, 2018, 319, 1444.	7.4	1,042
4	State of Telehealth. New England Journal of Medicine, 2016, 375, 154-161.	27.0	882
5	The Emerging Evidence of the Parkinson Pandemic. Journal of Parkinson's Disease, 2018, 8, S3-S8.	2.8	770
6	The Parkinson Pandemicâ€”A Call to Action. JAMA Neurology, 2018, 75, 9.	9.0	584
7	Technology in Parkinson's disease: Challenges and opportunities. Movement Disorders, 2016, 31, 1272-1282.	3.9	464
8	The mPower study, Parkinson disease mobile data collected using ResearchKit. Scientific Data, 2016, 3, 160011.	5.3	439
9	The Anatomy of Medical Research. JAMA - Journal of the American Medical Association, 2015, 313, 174.	7.4	342
10	Using Smartphones and Machine Learning to Quantify Parkinson Disease Severity. JAMA Neurology, 2018, 75, 876.	9.0	303
11	Funding of US Biomedical Research, 2003-2008. JAMA - Journal of the American Medical Association, 2010, 303, 137.	7.4	291
12	The Anatomy of Health Care in the United States. JAMA - Journal of the American Medical Association, 2013, 310, 1947.	7.4	257
13	The Influence of Controllable Lifestyle and Sex on the Specialty Choices of Graduating U.S. Medical Students, 1996???2003. Academic Medicine, 2005, 80, 791-796.	1.6	251
14	A roadmap for implementation of patientâ€centered digital outcome measures in Parkinson's disease obtained using mobile health technologies. Movement Disorders, 2019, 34, 657-663.	3.9	213
15	Impact of FDA Black Box Advisory on Antipsychotic Medication Use. Archives of Internal Medicine, 2010, 170, 96.	3.8	211
16	Optimal Expectations and Limited Medical Testing: Evidence from Huntington Disease. American Economic Review, 2013, 103, 804-830.	8.5	201
17	Randomized Controlled Clinical Trial of â€œVirtual House Callsâ€•for Parkinson Disease. JAMA Neurology, 2013, 70, 565.	9.0	201
18	Telemedicine 2020 and the next decade. Lancet, The, 2020, 395, 859.	13.7	196

#	Article	IF	Citations
19	The Coronavirus Disease 2019 Crisis as Catalyst for Telemedicine for Chronic Neurological Disorders. JAMA Neurology, 2020, 77, 927.	9.0	183
20	Teleneurology and mobile technologies: the future of neurological care. Nature Reviews Neurology, 2018, 14, 285-297.	10.1	173
21	National randomized controlled trial of virtual house calls for Parkinson disease. Neurology, 2017, 89, 1152-1161.	1.1	169
22	Increasing access to specialty care: A pilot, randomized controlled trial of telemedicine for Parkinson's disease. Movement Disorders, 2010, 25, 1652-1659.	3.9	153
23	The coming crisis. Neurology, 2013, 80, 1989-1996.	1.1	144
24	The past, present, and future of telemedicine for Parkinson's disease. Movement Disorders, 2014, 29, 871-883.	3.9	141
25	The Use of Smartphones for Health Research. Academic Medicine, 2017, 92, 157-160.	1.6	138
26	Therapeutic approaches to Huntington disease: from the bench to the clinic. Nature Reviews Drug Discovery, 2018, 17, 729-750.	46.4	117
27	Integrated and patient-centred management of Parkinson's disease: a network model for reshaping chronic neurological care. Lancet Neurology, The, 2020, 19, 623-634.	10.2	110
28	Limited Life Expectancy, Human Capital and Health Investments. American Economic Review, 2013, 103, 1977-2002.	8.5	108
29	The First Frontier: Digital Biomarkers for Neurodegenerative Disorders. Digital Biomarkers, 2017, 1, 6-13.	4.4	100
30	Improving Access to Care: Telemedicine Across Medical Domains. Annual Review of Public Health, 2021, 42, 463-481.	17.4	98
31	Motor, cognitive, and functional declines contribute to a single progressive factor in early HD. Neurology, 2017, 89, 2495-2502.	1.1	97
32	Novel Methods and Technologies for 21st-Century Clinical Trials. JAMA Neurology, 2015, 72, 582.	9.0	95
33	Moving Parkinson care to the home. Movement Disorders, 2016, 31, 1258-1262.	3.9	94
34	A Randomized, Placebo-Controlled Trial of Latrepirdine in Huntington Disease. Archives of Neurology, 2010, 67, 154.	4.5	87
35	Nursing home and end-of-life care in Parkinson disease. Neurology, 2015, 85, 413-419.	1.1	87
36	Natural History of Huntington Disease. JAMA Neurology, 2013, 70, 1520-30.	9.0	84

#	Article	IF	Citations
37	Remote smartphone monitoring of Parkinsonâ€™s disease and individual response to therapy. Nature Biotechnology, 2022, 40, 480-487.	17.5	73
38	Care, Convenience, Comfort, Confidentiality, and Contagion: The 5 Câ€™s that Will Shape the Future of Telemedicine. Journal of Parkinson's Disease, 2020, 10, 893-897.	2.8	70
39	Patient and Physician Perceptions of Virtual Visits for Parkinson's Disease: A Qualitative Study. Telemedicine Journal and E-Health, 2018, 24, 255-267.	2.8	69
40	Telemedicine in Leading US Neurology Departments. Neurohospitalist, The, 2012, 2, 123-128.	0.8	57
41	Telemedicine for the care of nursing home residents with Parkinson's disease. Movement Disorders, 2009, 24, 1073-1076.	3.9	52
42	Virtual visits for Parkinson disease. Neurology: Clinical Practice, 2014, 4, 146-152.	1.6	52
43	Wearable Sensors in Huntington Disease: A Pilot Study. Journal of Huntington's Disease, 2016, 5, 199-206.	1.9	52
44	Feasibility of Virtual Research Visits inÂFoxÂTrial Finder. Journal of Parkinson's Disease, 2015, 5, 505-515.	2.8	50
45	Patient Views on Telemedicine for Parkinson Disease. Journal of Parkinson's Disease, 2019, 9, 401-404.	2.8	49
46	A Pilot Study of Virtual Visits in Huntington Disease. Journal of Huntington's Disease, 2014, 3, 189-195.	1.9	47
47	National Randomized Controlled Trial of Virtual House Calls for People with Parkinson's Disease: Interest and Barriers. Telemedicine Journal and E-Health, 2016, 22, 590-598.	2.8	47
48	Advancing the Use of Mobile Technologies in Clinical Trials: Recommendations from the Clinical Trials Transformation Initiative. Digital Biomarkers, 2020, 3, 145-154.	4.4	47
49	Financial anatomy of neuroscience research. Annals of Neurology, 2006, 60, 652-659.	5.3	46
50	A U.S. survey of patients with Parkinson's disease: Satisfaction with medical care and support groups. Movement Disorders, 2010, 25, 2128-2135.	3.9	45
51	Telehealth Management of Parkinsonâ€™s Disease Using Wearable Sensors: An Exploratory Study. Digital Biomarkers, 2017, 1, 43-51.	4.4	45
52	The New Normal in Clinical Trials: Decentralized Studies. Annals of Neurology, 2020, 88, 863-866.	5.3	45
53	Preventing Parkinsonâ€™s Disease: An Environmental Agenda. Journal of Parkinson's Disease, 2022, 12, 45-68.	2.8	45
54	Financing of U.S. Biomedical Research and New Drug Approvals across Therapeutic Areas. PLoS ONE, 2009, 4, e7015.	2.5	44

#	Article	IF	Citations
55	The Parkinson's disease eâ€diary: Developing a clinical and research tool for the digital age. Movement Disorders, 2019, 34, 676-681.	3.9	43
56	Deep Phenotyping of Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2020, 10, 855-873.	2.8	42
57	Incorporating Site-less Clinical Trials Into Drug Development: A Framework for Action. Clinical Therapeutics, 2017, 39, 1064-1076.	2.5	40
58	Distribution of Medical Education Debt by Specialty, 2010-2016. JAMA Internal Medicine, 2017, 177, 1532.	5.1	38
59	State of Telehealth. New England Journal of Medicine, 2016, 375, 1399-1400.	27.0	37
60	A New Day: The Role of Telemedicine in Reshaping Care for Persons With Movement Disorders. Movement Disorders, 2020, 35, 1897-1902.	3.9	37
61	Patient-reported impact of symptoms in Huntington disease. Neurology, 2020, 94, e2045-e2053.	1.1	37
62	Passive Monitoring at Home: A Pilot Study in Parkinson Disease. Digital Biomarkers, 2019, 3, 22-30.	4.4	36
63	Virtual visits for Parkinson disease. Neurology: Clinical Practice, 2017, 7, 283-295.	1.6	35
64	Feasibility, Reliability, and Value of Remote Video-Based Trial Visits in Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2020, 10, 1779-1786.	2.8	33
65	The McDonaldization of Medicine. JAMA Neurology, 2016, 73, 15.	9.0	29
66	Symptom burden among individuals with Parkinson disease. Neurology: Clinical Practice, 2020, 10, 65-72.	1.6	29
67	Genetic modifiers of Huntington disease differentially influence motor and cognitive domains. American Journal of Human Genetics, 2022, 109, 885-899.	6.2	29
68	Communicating Clinical Trial Results to Research Participants. Archives of Neurology, 2008, 65, 1590.	4.5	28
69	The PARK Framework for Automated Analysis of Parkinson's Disease Characteristics. , 2019, 3, 1-22.		28
70	Smartphones as new tools in the management and understanding of Parkinsonâ€™s disease. Npj Parkinson's Disease, 2016, 2, 16006.	5.3	27
71	Remote Administration of the MDS-UPDRS in the Time of COVID-19 and Beyond. Journal of Parkinson's Disease, 2020, 10, 1379-1382.	2.8	27
72	Direct-to-consumer digital health. The Lancet Digital Health, 2020, 2, e163-e165.	12.3	27

#	Article	IF	Citations
73	An Evaluation of Four Proposals to Reduce the Financial Burden of Medical Education. Academic Medicine, 2006, 81, 245-251.	1.6	25
74	Virtual house calls for Parkinson disease (Connect.Parkinson): study protocol for a randomized, controlled trial. Trials, 2014, 15, 465.	1.6	25
75	Crowdsourcing digital health measures to predict Parkinsonâ€™s disease severity: the Parkinsonâ€™s Disease Digital Biomarker DREAM Challenge. Npj Digital Medicine, 2021, 4, 53.	10.9	24
76	A real-world study of wearable sensors in Parkinsonâ€™s disease. Npj Parkinson's Disease, 2021, 7, 106.	5.3	24
77	Biomarkers in Parkinsonâ€™s disease. Expert Review of Neurotherapeutics, 2006, 6, 823-831.	2.8	23
78	The Economics of New Faculty Hires in Basic Science. Academic Medicine, 2009, 84, 26-31.	1.6	22
79	Virtual research visits and direct-to-consumer genetic testing in Parkinsonâ€™s disease. Digital Health, 2015, 1, 205520761559299.	1.8	22
80	Telemedicine Use for Movement Disorders: A Global Survey. Telemedicine Journal and E-Health, 2018, 24, 979-992.	2.8	22
81	Forgiven but not Relieved: US Physician Workforce Consequences of Changes to Public Service Loan Forgiveness. Journal of General Internal Medicine, 2016, 31, 1237-1241.	2.6	21
82	An Update on Parkinson's Disease: Improving Patient Outcomes. American Journal of Medicine, 2014, 127, S3.	1.5	20
83	Development of digital measures for nighttime scratch and sleep using wrist-worn wearable devices. Npj Digital Medicine, 2021, 4, 42.	10.9	20
84	A Longitudinal Wearable Sensor Study in Huntingtonâ€™s Disease. Journal of Huntington's Disease, 2020, 9, 69-81.	1.9	19
85	Design of a virtual longitudinal observational study in Parkinsonâ€™s disease (ATâ€HOME PD). Annals of Clinical and Translational Neurology, 2021, 8, 308-320.	3.7	18
86	Optimal Expectations and Limited Medical Testing: Evidence from Huntington Disease: Corrigendum. American Economic Review, 2016, 106, 1562-1565.	8.5	17
87	Commentary: Improving the Supply and Distribution of Primary Care Physicians. Academic Medicine, 2011, 86, 541-543.	1.6	15
88	Depressed Mood and Suicidality in Individuals Exposed to Tetrabenazine in a Large Huntington Disease Observational Study. Journal of Huntington's Disease, 2013, 2, 509-515.	1.9	15
89	Video research visits for atypical parkinsonian syndromes among Fox Trial Finder participants. Neurology: Clinical Practice, 2020, 10, 7-14.	1.6	15
90	Detecting Parkinson Disease Using a Web-Based Speech Task: Observational Study. Journal of Medical Internet Research, 2021, 23, e26305.	4.3	15

#	Article	IF	Citations
91	Practicing in a Pandemic. Neurology: Clinical Practice, 2021, 11, e179-e188.	1.6	15
92	Hospital care for mental health and substance abuse conditions in Parkinson's disease. Movement Disorders, 2016, 31, 1810-1819.	3.9	14
93	Telemedicine for Parkinson's Disease: Limited Engagement Between Local Clinicians and Remote Specialists. Telemedicine Journal and E-Health, 2018, 24, 722-724.	2.8	13
94	The Best Digital Biomarkers Papers of 2017. Digital Biomarkers, 2018, 2, 64-73.	4.4	12
95	Recruitment for Remote Decentralized Studies in Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2022, 12, 371-380.	2.8	12
96	GEORGEÂ®: A Pilot Study of a Smartphone Application for Huntingtonâ€™s Disease. Journal of Huntington's Disease, 2021, 10, 293-301.	1.9	11
97	The new platforms of health care. Npj Digital Medicine, 2021, 4, 112.	10.9	11
98	Caring for the majority. Movement Disorders, 2013, 28, 261-262.	3.9	10
99	Inaugural Conference on Incorporating Patient-Reported Outcomes and Patient Preference Information into Clinical Research, Clinical Care, and Risk-Benefit Assessments for Neurodegenerative Diseases. Patient, 2017, 10, 541-544.	2.7	10
100	The TOPAZ study: a home-based trial of zoledronic acid to prevent fractures in neurodegenerative parkinsonism. Npj Parkinson's Disease, 2021, 7, 16.	5.3	10
101	Neurohospitalists: Perceived Need and Training Requirements in Academic Neurology. Neurohospitalist, The, 2014, 4, 9-17.	0.8	9
102	Seeking progress in disease modification in Parkinson disease. Parkinsonism and Related Disorders, 2021, 90, 134-141.	2.2	9
103	United States trends in thrombolysis for older adults with acute ischemic stroke. Clinical Neurology and Neurosurgery, 2015, 139, 16-23.	1.4	8
104	A Virtual Cohort Study of Individuals at Genetic Risk for Parkinsonâ€™s Disease: Study Protocol and Design. Journal of Parkinson's Disease, 2020, 10, 1195-1207.	2.8	8
105	Impact of 2011 Resident Duty Hour Requirements on Neurology Residency Programs and Departments. Neurohospitalist, The, 2014, 4, 119-126.	0.8	7
106	A Digital Journal for a Digital Era. Digital Biomarkers, 2017, 1, 1-3.	4.4	7
107	Metadata Framework to Support Deployment of Digital Health Technologies in Clinical Trials in Parkinsonâ€™s Disease. Sensors, 2022, 22, 2136.	3.8	7
108	Funding of Parkinson research from industry and US federal and foundation sources. Movement Disorders, 2009, 24, 731-737.	3.9	6

#	Article	IF	Citations
109	The triple aim of clinical research. Clinical Trials, 2021, 18, 511-513.	1.6	6
110	A Smartphone Application as an Exploratory Endpoint in a Phase 3 Parkinsonâ€™s Disease Clinical Trial: A Pilot Study. Digital Biomarkers, 2022, 6, 1-8.	4.4	6
111	Informativeness of Early Huntington DiseaseÂSignsÂaboutÂGeneÂStatus. Journal of Huntington's Disease, 2015, 4, 271-277.	1.9	5
112	Spatio-Temporal Attention and Magnification for Classification of Parkinsonâ€™s Disease from Videos Collected via the Internet. , 2020, , .		5
113	Identifying and characterising sources of variability in digital outcome measures in Parkinsonâ€™s disease. Npj Digital Medicine, 2022, 5, .	10.9	5
114	Bad Air and Parkinson Diseaseâ€”The Fog May Be Lifting. JAMA Neurology, 2021, 78, 793.	9.0	4
115	Choosing Wisely. Neurology, 2013, 81, 946-947.	1.1	3
116	Opinion and Special Articles: Loan forgiveness options for young neurologists. Neurology, 2017, 88, e153-e156.	1.1	3
117	Using Technology to Reshape Clinical Care and Research in Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2021, 11, S1-S3.	2.8	3
118	Shining light on Medicare's values. Neurology, 2015, 84, 1730-1731.	1.1	2
119	Neurologic care ... anytime?. Neurology: Clinical Practice, 2016, 6, 472-474.	1.6	2
120	The Huntingtonâ€™s Disease Health Index: Initial Evaluation of a Disease-Specific Patient Reported Outcome Measure. Journal of Huntington's Disease, 2022, 11, 217-226.	1.9	2
121	Cost vs care. Neurology, 2019, 93, 985-986.	1.1	1
122	A Blueprint for the Conduct of Large, Multisite Trials in Telemedicine. Journal of Medical Internet Research, 2021, 23, e29511.	4.3	1
123	Predicting Parkinson's Disease with Multimodal Irregularly Collected Longitudinal Smartphone Data. , 2020, , .		1
124	Silent majority. Neurology: Clinical Practice, 2016, 6, 11-13.	1.6	0
125	Applying the Principles of McDonaldization to Medicineâ€”Reply. JAMA Neurology, 2016, 73, 479.	9.0	0
126	Comment: The virtual neurologist. Neurology, 2017, 89, 161-161.	1.1	0

#	Article	IF	Citations
127	The Inaugural Issue. Digital Biomarkers, 2017, 1, , sgmppl =-5.	4.4	0
128	Telemedicine and Parkinsonâ€™s Disease. , 2015, , 105-112.		0
129	Next Generation House Call. Cerebrum: the Dana Forum on Brain Science, 2017, 2017, .	0.1	0